For UK Healthcare Professionals only
GP Notebook
This content has been written and funded by Boehringer Ingelheim

The sounds of Idiopathic Pulmonary Fibrosis (IPF)

IPF is not just a challenging disease, it is also difficult to diagnose. Early symptoms such as dyspnoea on exertion and dry cough can be diagnosed as part of another respiratory disease. The assessment of "velcro crackles" by lung auscultation is currently the only realistic means for the earlier diagnosis of IPF.1

Use the following example patient sounds to compare the differences between IPF, chronic obstructive pulmonary disease (COPD) and those of a healthy person.

OFEV® (nintedanib) is indicated in adults for the treatment of idiopathic pulmonary fibrosis and other chronic fibrosing interstitial lung diseases with a progressive phenotype.2

Please click here for prescribing information

Adverse event reporting details are at the bottom of this webpage

Take the IPF Sound Challenge

The IPF sound challenge allows you to practice identifying various respiratory conditions, including IPF.

The IPF Sound Challenge

The links below allow you to view additional information about the signs and symptoms of IPF:

IPF = Idiopathic Pulmonary Fibrosis
  1. Cottin V, et al. Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis? Eur Respir J 2012;40:519–521.
  2. OFEV® 100 mg and 150 mg soft capsules Summary of Product Characteristics. Boehringer Ingelheim.

PC-GB-103324 v3

January 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone)
Prescribing information for Great Britain and Northern Ireland
Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard (UK) or https://www.hpra.ie/homepage/about-us/report-an-issue (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) (UK) or 01 2913960 (IRE), Fax: +44 1344 742661, or by e-mail: [email protected].


You are leaving this site.

You are now leaving https://resources.gpnotebook.com/moving-forward-in-type-2-diabetes-management-with-glp-1ras-resource-hub/.
Links to external website are provided as a resource to the viewer.
This website is neither owned or controlled by Novo Nordisk.
Novo Nordisk accepts no responsibility for the content or services of the linked site.

For UK Healthcare Professionals only

Are you a healthcare professional?

The information is intended for healthcare professionals only.
Please confirm below.